



A



B



Supp Figure S8. (A) In the parental cells, blockade of EGFR signaling inhibits a variety of downstream signaling pathways, including PI3K, JAK-STAT, PLC-PKC and MAPK. (B) In a Cetuximab-resistant clone that has acquired an activating mutation in BRAF (asterisk), treatment of the cells with Cetuximab fails to suppress MAPK signaling and cells continue to proliferate. Only when a BRAF inhibitor is combined with Cetuximab are all the relevant signaling pathways inhibited and cell survival/proliferation reduced.